Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils
Abstract
:1. Introduction
2. Materials and Methods
2.1. Samples
2.2. HPLC Analysis
2.3. Sample Preparation for HPLC
2.4. Antioxidant Assay
3. Results
3.1. HPLC Analysis of CBD and Hemp Seed Oils
3.2. Biological Activities of CBD and Hemp Seed Oils
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Gould, J. The Cannabis Crop. Nature 2015, 525, S2–S3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- ElSohly, M.A.; Radwan, M.M.; Gul, W.; Chandra, S.; Galal, A. Phytochemistry of Cannabis Sativa L. Prog. Chem. Org. Nat. Prod. 2017, 103, 1–36. [Google Scholar]
- Pertwee, R.G. The Diverse CB 1 and CB 2 Receptor Pharmacology of Three Plant Cannabinoids: Δ 9-Tetrahydrocannabinol, Cannabidiol and Δ 9-Tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153, 199–215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Press, C.A.; Knupp, K.G.; Chapman, K.E. Parental Reporting of Response to Oral Cannabis Extracts for Treatment of Refractory Epilepsy. Epilepsy Behav. 2015, 45, 49–52. [Google Scholar] [CrossRef] [PubMed]
- Moreira, F.A.; Aguiar, D.C.; Guimarães, F.S. Anxiolytic-like Effect of Cannabidiol in the Rat Vogel Conflict Test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30, 1466–1471. [Google Scholar] [CrossRef]
- Campos, A.C.; Fogaça, M.V.; Sonego, A.B.; Guimarães, F.S. Cannabidiol, Neuroprotection and Neuropsychiatric Disorders. Pharmacol. Res. 2016, 112, 119–127. [Google Scholar] [CrossRef]
- VanDolah, H.J.; Bauer, B.A.; Mauck, K.F. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin. Proc. 2019, 94, 1840–1851. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mannucci, C.; Navarra, M.; Calapai, F.; Spagnolo, E.V.; Busardò, F.P.; Cas, R.D.; Ippolito, F.M.; Calapai, G. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol. Disord. Drug Targets 2017, 16, 541–553. [Google Scholar] [CrossRef] [Green Version]
- Da Porto, C.; Decorti, D.; Tubaro, F. Fatty Acid Composition and Oxidation Stability of Hemp (Cannabis Sativa L.) Seed Oil Extracted by Supercritical Carbon Dioxide. Ind. Crops Prod. 2012, 36, 401–404. [Google Scholar] [CrossRef]
- Petrović, M.; Debeljak, Ž.; Kezić, N.; Džidara, P. Relationship between Cannabinoids Content and Composition of Fatty Acids in Hempseed Oils. Food Chem. 2015, 170, 218–225. [Google Scholar] [CrossRef]
- Iwasaki, K.; Takayama, S. Hemp Seed Pill May Improve Chronic Constipation of the Elderly and Reduce the Burden of Helpers. J. Fam. Med. Prim. Care 2019, 8, 2150. [Google Scholar] [CrossRef] [PubMed]
- Citti, C.; Pacchetti, B.; Vandelli, M.A.; Forni, F.; Cannazza, G. Analysis of Cannabinoids in Commercial Hemp Seed Oil and Decarboxylation Kinetics Studies of Cannabidiolic Acid (CBDA). J. Pharm. Biomed. Anal. 2018, 149, 532–540. [Google Scholar] [CrossRef] [PubMed]
- Matsunaga, T.; Watanabe, K.; Yoshimura, H.; Yamamoto, I. Quantitative Analysis and Pharmaco-Toxicity of Cannabinoids in Commercially Available Cannabis Seeds. Yakugaku Zasshi 1998, 118, 408–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Russo, E.B.; Marcu, J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Adv. Pharmacol. 2017, 80, 67–134. [Google Scholar]
- Yan, X.; Tang, J.; Dos Santos Passos, C.; Nurisso, A.; Simoes-Pires, C.A.; Ji, M.; Lou, H.; Fan, P. Characterization of Lignanamides from Hemp (Cannabis Sativa L.) Seed and Their Antioxidant and Acetylcholinesterase Inhibitory Activities. J. Agric. Food Chem. 2015, 63, 10611–10619. [Google Scholar] [CrossRef]
- Nissen, L.; Zatta, A.; Stefanini, I.; Grandi, S.; Sgorbati, B.; Biavati, B.; Monti, A. Characterization and Antimicrobial Activity of Essential Oils of Industrial Hemp Varieties (Cannabis Sativa L.). Fitoterapia 2010, 81, 413–419. [Google Scholar] [CrossRef]
- Zengin, G.; Menghini, L.; Di Sotto, A.; Mancinelli, R.; Sisto, F.; Carradori, S.; Cesa, S.; Fraschetti, C.; Filippi, A.; Angiolella, L.; et al. Chromatographic Analyses, In Vitro Biological Activities, and Cytotoxicity of Cannabis Sativa L. Essential Oil: A Multidisciplinary Study. Molecules 2018, 23, 3266. [Google Scholar] [CrossRef] [Green Version]
- Hacke, A.C.M.; Lima, D.; de Costa, F.; Deshmukh, K.; Li, N.; Chow, A.M.; Marques, J.A.; Pereira, R.P.; Kerman, K. Probing the antioxidant activity of Δ9-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst 2019, 144, 4952–4961. [Google Scholar] [CrossRef]
- Mandrioli, M.; Tura, M.; Scotti, S.; Toschi, G.T. Fast Detection of 10 Cannabinoids by RP-HPLC-UV Method in Cannabis sativa L. Molecules 2019, 24, 2113. [Google Scholar] [CrossRef] [Green Version]
- Takao, K.; Toda, K.; Saito, T.; Sugita, Y. Synthesis of Amide and Ester Derivatives of Cinnamic Acid and Its Analogs: Evaluation of Their Free Radical Scavenging and Monoamine Oxidase and Cholinesterase Inhibitory Activities. Chem. Pharm. Bull. 2017, 65, 1020–1027. [Google Scholar] [CrossRef] [Green Version]
- Atolani, O.; Oguntoye, H.; Areh, E.T.; Adeyemi, O.S.; Kambizi, L. Chemical Composition, Anti-Toxoplasma, Cytotoxicity, Antioxidant, and Anti-Inflammatory Potentials of Cola Gigantea Seed Oil. Pharm. Biol. 2019, 57, 154–160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huestis, M.A.; Solimini, R.; Pichini, S.; Pacifici, R.; Carlier, J.; Busardò, F.P. Cannabidiol Adverse Effects and Toxicity. Curr. Neuropharmacol. 2019, 17, 974–989. [Google Scholar] [CrossRef] [PubMed]
Sample | Product | Product Origin |
---|---|---|
C1 | CBD oil | USA |
C2 | CBD oil | Unknown |
C3 | Hemp seed oil | Australia |
C4 | Hemp seed oil | New Zealand |
C5 | Hemp seed oil | Unknown |
C6 | Hemp seed oil | Germany |
C7 | Hemp seed oil | Germany |
C8 | Hemp seed oil | Canada |
C9 | Rapeseed oil | Japan |
Factors | Results |
---|---|
Equation | y = 18600x − 23348 |
R2 | 0.995 |
LOD (µg/mL) | 1.5 |
LOQ (µg/mL) | 4.6 |
RSD (Intra-Day) | 4.2% |
RSD (Inter-Day) | 2.4% |
Sample | Antioxidant Activity | |||
---|---|---|---|---|
DPPH | ABTS | |||
Sample Conc. (25 µL/mL) | IC50 (CBD) | Sample Conc. (25 µL/mL) | IC50 (CBD) | |
C1 | 64.8 ± 0.8% | 17.9 µL/mL (1075 µM) | 90.5 ± 0.1% | 2.3 µL/mL (138 µM) |
C2 | 63.2 ± 1.4% | 18.6 µL/mL (522 µM) | 90.3 ± 0.1% | 3.6 µL/mL (67 µM) |
C3 | 12.7 ± 0.8% | - | 28.2 ± 2.4% | - |
C4 | 23.2 ± 1.0% | - | 47.8 ± 2.0% | - |
C5 | 19.8 ± 0.4% | - | 21.8 ± 1.3% | - |
C6 | 11.1 ± 0.6% | - | 27.3 ± 1.1% | - |
C7 | 1.3 ± 0.8% | - | 2.8 ± 1.2% | - |
C8 | 11.6 ± 1.1% | - | 26.9 ± 1.0% | - |
C9 | 14.5 ± 0.6% | - | 36.6 ± 1.9% | - |
Ascorbic Acid | - | 38.0 µM | - | 11.3 µM |
CBD | - | 584 µM | - | 92.2 µM |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kitamura, M.; Kiba, Y.; Suzuki, R.; Tomida, N.; Uwaya, A.; Isami, F.; Deng, S. Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils. Medicines 2020, 7, 57. https://doi.org/10.3390/medicines7090057
Kitamura M, Kiba Y, Suzuki R, Tomida N, Uwaya A, Isami F, Deng S. Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils. Medicines. 2020; 7(9):57. https://doi.org/10.3390/medicines7090057
Chicago/Turabian StyleKitamura, Masashi, Yuka Kiba, Ryuichiro Suzuki, Natsumi Tomida, Akemi Uwaya, Fumiyuki Isami, and Shixin Deng. 2020. "Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils" Medicines 7, no. 9: 57. https://doi.org/10.3390/medicines7090057
APA StyleKitamura, M., Kiba, Y., Suzuki, R., Tomida, N., Uwaya, A., Isami, F., & Deng, S. (2020). Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils. Medicines, 7(9), 57. https://doi.org/10.3390/medicines7090057